Second-generation tyrosine kinase inhibitors for chronic myeloid leukemia

Giuseppe Saglio

At the 20th Congress of the European Hematology Association (EHA), Giuseppe Saglio, MD, of the University of Turin, Turin, Italy, discusses the role of second-generation tyrosine kinase inhibitors (TKIs), nilotinib and dasatinib, in the management of patients with chronic myeloid leukemia (CML).

Share this video  
Chronic Myeloid Leukemia
Dasatinib, Nilotinib
EHA 2015
12th June 2015
More from Giuseppe Saglio
Update on the efficacy and safety of tyrosine kinase inhibitors for chronic myeloid leukemia
Results of the Phase III DASISION trial and the future of CML treatment
Is it possible to reach an operational cure for CML?
VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

The content of VJHemOnc is intended for healthcare professionals